VIGABATRIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for vigabatrin and what is the scope of patent protection?
Vigabatrin
is the generic ingredient in five branded drugs marketed by Lundbeck Pharms Llc, Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms, Annora Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Dexcel, Dr Reddys, Endo Operations, Granules, Invagen Pharms, MSN, Propel Pharma, Specgx Llc, Teva Pharms Usa, Zydus Lifesciences, Aucta, Pyros Pharms, Hikma, Ryan Labs, and Upsher Smith Labs, and is included in thirty NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Vigabatrin has three patent family members in two countries.
There are five drug master file entries for vigabatrin. Seventeen suppliers are listed for this compound.
Summary for VIGABATRIN
International Patents: | 3 |
US Patents: | 1 |
Tradenames: | 5 |
Applicants: | 22 |
NDAs: | 30 |
Drug Master File Entries: | 5 |
Finished Product Suppliers / Packagers: | 17 |
Raw Ingredient (Bulk) Api Vendors: | 121 |
Clinical Trials: | 30 |
Patent Applications: | 5,913 |
Drug Prices: | Drug price trends for VIGABATRIN |
What excipients (inactive ingredients) are in VIGABATRIN? | VIGABATRIN excipients list |
DailyMed Link: | VIGABATRIN at DailyMed |
Recent Clinical Trials for VIGABATRIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Amzell | Phase 3 |
University of Florida | Phase 2 |
Yale University | Phase 2 |
Pharmacology for VIGABATRIN
Drug Class | Anti-epileptic Agent |
Medical Subject Heading (MeSH) Categories for VIGABATRIN
Anatomical Therapeutic Chemical (ATC) Classes for VIGABATRIN
US Patents and Regulatory Information for VIGABATRIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dexcel | VIGABATRIN | vigabatrin | TABLET;ORAL | 215109-001 | Sep 23, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Msn | VIGABATRIN | vigabatrin | FOR SOLUTION;ORAL | 215363-001 | Sep 7, 2022 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Propel Pharma | VIGABATRIN | vigabatrin | FOR SOLUTION;ORAL | 213390-001 | Jul 29, 2021 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Chartwell Rx | VIGABATRIN | vigabatrin | FOR SOLUTION;ORAL | 211790-001 | Mar 10, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VIGABATRIN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
ORPHELIA Pharma SAS | Kigabeq | vigabatrin | EMEA/H/C/004534 Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. |
Authorised | no | no | no | 2018-09-20 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VIGABATRIN
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
United Kingdom | 202103724 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2020039262 | ⤷ Sign Up | |
United Kingdom | 2591389 | Pharmaceuticals solution for oral dosage | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.